Abstract
Fibromyalgia (FM) is a non-articular rheumatic disease, a chronic and heterogeneous condition in which the patient has diffuse musculoskeletal pain, in addition to associated symptoms such as fatigue, sleep disorders, stiffness and a subjective sensation of swelling. FM is directly related to the loss of quality of life, therefore, the therapeutic objective is to provide comprehensive and comprehensive treatment. In the pharmacological management of FM, pregabalin and duloxetine are the pharmacological agents indicated by the Food and Drug Administration (FDA) to alleviate symptoms and improve the quality of life of patients with this chronic condition. The present study aims to identify the impact of adverse effects on adherence to pharmacological therapy in patients with FM, evaluating the types and frequencies of these effects and investigating the comparative efficacy of pregabalin and duloxetine in the context of treatment. An integrative literature review was carried out from the PubMed and BVS databases using Boolean descriptors and terms: Fibromyalgia AND Treatment AND Adverse Effects AND Adherence. Twenty-two full articles published from 2019 to 2024 were included. The results indicate that pregabalin was associated with blurred vision, cognitive effects, sedation and weight gain, while duloxetine, in turn, has adverse effects such as insomnia, constipation, dizziness and headache and, more rarely, acid reflux. These effects often make it difficult and can lead to treatment abandonment. We detected that treatment adherence is often compromised due to the variety of adverse effects that impact patients' quality of life. We highlight the relevance of adopting non-pharmacological measures to ensure more effective treatment. It is concluded that knowledge of the main adverse effects is of paramount importance to optimize treatment adherence and patients' quality of life, in addition to the inclusion of non-pharmacological measures, such as physical exercise and psychotherapy.
References
Abdelaziz, N. G. et al. The effect of physical therapy rehabilitation on fatigue and pain in female patients with fibromyalgia. Sport TK-EuroAmerican Journal of Sport Sciences, v. 13, supl. 1, art. 34, 2024.
Alvarez-Mon MA, García-Montero C, Fraile-Martinez O, Quintero J, Fernandez-Rojo S, Mora F, Gutiérrez-Rojas L, Molina-Ruiz RM, Lahera G, Ortega MA. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci. 2023 Feb.
Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019 Jun;
Carneiro, L. S. et al. Exercise Training for Women With Fibromyalgia Syndrome. Topics in Geriatric Rehabilitation, 2024. DOI: 10.1097/tgr.0000000000000435.
Cross AL, Viswanath O, Sherman AL. Pregabalin. 2022 Nov 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
FARAG HM, Yunusa I, Goswami H, Sultan I, Doucette JA, Eguale T. Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis. JAMA Netw Open. Mai 2022.
GÜL ŞK, Tepetam H, Gül HL. Duloxetine and pregabalin in neuropathic pain of lung cancer patients. Brain Behav. Mai 2023.
ILARI S, Passacatini LC, Malafoglia V, et al. Tantali fibromyalgic supplicium: Is there any relief with the antidepressant employment? A systematic review. Pharmacol Res. 2022.
Jones EA, Asaad F, Patel N, Jain E, Abd-Elsayed A. Management of Fibromyalgia: An Update. Biomedicines. 2024 Jun.
José, E. et al. Fibromyalgia - are there any new approaches? Best Practice & Research: Clinical Rheumatology, 2024, p. 101933. DOI: 10.1016/j.berh.2024.101933.
KÜMPEL C, Porto EF, Silva KMOM, Aguiar SD, Lima PB, Campos GF, et al. Estudo comparativo dos efeitos da hidroterapia e método Pilates sobre a capacidade funcional de pacientes portadores de fibromialgia. Acta Fisiatr.2020;
LEE, Jeong-Won et al. Determinants of quality of life in patients with fibromyalgia: A structural equation modeling approach. Plos one, 2017.
McAnally H, Bonnet U, Kaye AD. Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth. Pain Ther. 2020 Dec;9(2):441-452. Epub 2020 Jul 31. Erratum in: Pain Ther. 2021 Jun.
MCDONAGG, M.S, Selph SS, Buckley DI, et al. Nonopioid Pharmacologic Treatments for Chronic Pain. Agency for Healthcare Research and Quality, Abr 2020.
PREUSS, C.V, et al. Prescription of Controlled Substances: Benefits and Risks. Jan 2023.
ROSSI A, Di Lollo AC, Guzzo MP, et al. Fibromyalgia and nutrition: what news?. Clin ExpRheumatol. 2015.
Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Front Psychiatry. 2020 Oct
Rico-Villademoros F, Postigo-Martin P, Garcia-Leiva JM, Ordoñez-Carrasco JL, Calandre EP. Patterns of pharmacologic and non-pharmacologic treatment, treatment satisfaction and perceived tolerability in patients with fibromyalgia: a patients' survey. Clin Exp Rheumatol. 2020 Jan-Feb;
SIRACUSA, Rosalba et al. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. International Journal of Molecular Sciences, 2021.
SBR. R. E. Heymann, et al. Consenso brasileiro do tratamento da fibromialgia. Rev BrasReumatol 2010;
Vaghela N, Jadav N, Kollampare S, Patel P, Oza M. Acid Reflux: A Rare Adverse Effect ofDuloxetine. Cureus. 2023 Jul 23;
Velioglu O, Yildizgoren MT, Ogut H, Guler H, Turhanoglu AD. Short‑term effects of pregabalin plus exercise therapy on pain, emotional status, physical function and nociceptive responses in patients with fibromyalgia. Med Int (Lond). 2023 Aug
Yang Y, Li YT, Sun YR, Wang J, Li Y, Zhang JH, Jiao J, Jiang Q. Therapeutic Effects of Ba-Duan-Jin versus Pregabalin for Fibromyalgia Treatment: Protocol for a Randomized Controlled Trial. Rheumatol Ther. 2021
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011
Zhang X, Xu H, Zhang Z, Li Y, Pauer L, Liao S, Zhang F. Efficacy and Safety of Pregabalinfor Fibromyalgia in a Population of Chinese Subjects. J Pain Res. 2021 Feb

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Renata Beatriz Almeida Tavares, Andréa Silva Ferreira, Fernanda Beatriz Santos Silveira, Jennifer Camila de Souza Fornari, José Suelton Luiz Costa Dos Santos , Juliana Monroy Leite, Luma Carolyne Araújo Costa, Maria Eduarda Pereira Dantas, Nayara Alves Santos Miranda , Rafael Cruz Mariz, Alejandra Debbo, Sabrina Oliveira Santos